Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$432,860
New position
Shares Held
2,762
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#957
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $7,172,969 across 8 Drug Manufacturers - General names. NVS ranks #7 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
28,898 | $1,665,102 | |
| 2 | LLY |
ELI LILLY & Co
|
1,075 | $1,289,387 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
9,877 | $1,247,860 | |
| 4 | AMGN |
Amgen Inc
|
2,641 | $956,358 | |
| 5 | GRFS |
Grifols SA
|
101,833 | $720,977 | |
| 6 | SNY |
Sanofi
|
12,660 | $540,075 | |
| 7 | NVS |
Novartis AG
This page
|
2,762 | $432,860 | |
| 8 | MRK |
Merck & Co., Inc.
|
2,493 | $320,350 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $432,860 | 2,762 | Shares | Sole | 2026-08-06 | |
| No filing history on record for this holder in this stock. | ||||||